Christopher Kroeger
Director
Medicine
Spi Prohealth
China
Biography
Dr. Kroeger joined OvaScience as Chief Executive Officer in September 2017. He brings more than 20 years of experience leading, building and advising development-stage therapeutic and medical device companies, as well as the expertise of a physician and scientist. Most recently, he served as CEO of Cardioxyl Pharmaceuticals, leading teams that produced three investigational new drug candidates and successfully executed six Phase 1 and Phase 2 clinical studies, culminating in the sale of the company to Bristol Myers Squibb for $2.1 billion in total consideration. Prior to his position at Cardioxyl, he led investing efforts as a Partner at The Aurora Funds, a venture capital firm focused on early-stage biotechnology and medical device companies. Earlier in his career, he held positions at Genzyme and Decision Resources.
Research Interest
Pharmaceutical Science
